Editas Medicine Announces First Quarter 2020 Results and Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Editas Medicine (EDIT) Tops Q1 EPS by 8c
May 7, 2020 7:48 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.69), $0.08 better than the analyst estimate of ($0.77).
The COVID-19 pandemic has given rise to unprecedented circumstances for Editas and the broader life sciences community, said Cynthia Collins, Chief Executive Officer of Editas Medicine. Our top priority is safety and we have implemented measures to ensure that safety comes first while mitigating the disruption to our... More
